Amicus Therapeutics sets IPO at 5 million shares

WASHINGTON, May 17 (Reuters) - Biopharmaceutical firm Amicus Therapeutics Inc. on Thursday set its planned initial public offering at 5 million shares for an estimated $14 to $16 each.

Morgan Stanley, Merrill Lynch & Co., JPMorgan, Lazard Capital Markets, and Pacific Growth Equities LLC are underwriting the IPO, according to an amended filing with the U.S. Securities and Exchange Commission.

Amicus intends to list its stock on the Nasdaq under the symbol "FOLD." (FOLD.O)

((Reporting by Karey Wutkowski, Reuters Messaging: karey.wutkowski.reuters.com@reuters.net; E-mail:karey.wutkowski@reuters.com +1 202 898 8399)) Keywords: AMICUS IPO/

(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nN17265013